Recent real-world study in community hospital setting reported amplicon-based NGS can provide genomic profiling results with a routine TAT of 3-days or less.
This study evaluated the feasibility of in-house fast NGS in a streamlined workflow at a community hospital on 578 consecutive solid tumor samples covering different cancer types, including lung cancer, melanoma, and colorectal carcinoma.
Genomic profiling in precision oncology is transforming cancer care. But long waiting periods for biomarker test results from the lab can delay treatment decisions.
Explore how fast in house genomic profiling changes the oncology patients journey and helps to improve their outcomes.
Democratization of NGS is the key to accelerating cancer care.
"Significantly shorter time to results enables faster and optimal treatment decisions."
"It improves care coordination between multidisciplinary teams, leading to true personalized medicine."
"Small sample requirement provides biopsy stewardship,
"Allows for the development of local expertise in biomarker testing to support the future of precision medicine."